← Leaderboards
Manuel L Penichet
University Of California Los Angeles
$9,583,462
Attributed
$13,961,352
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,961,352 · 9
By mechanism
R01$12,623,842 · 5
K01$631,770 · 1
R21$368,445 · 1
T32$178,444 · 1
R41$158,851 · 1
Top collaborators
- Julia Y Ljubimova7 shared
- Otoniel Martinez-Maza7 shared
- Brian B. Gowen3 shared
- Timothy R Donahue1 shared
- Birgit C Schultes1 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Otoniel Martinez-Maza$22,455,072
- Brian B. Gowen$3,198,237
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesCellsIn VitroTumorCancer CellMalignant NeoplasmsBaseAffinityChimeric ProteinsReceptor Mediated EndocytosisDoseMediatingImmune ResponseExhibitsComplexPharmaceutical PreparationsAntineoplastic AgentsIgg3Cell LineAntigensOverexpressionReceptorScid MiceAvidin
Grant awards (39)
Antibody-based therapeutic strategy for New World mammarenavirus hemorrhagic fever$731,002
R01 · FY2025 · AI · contact PI
UCLA Surgeon-Scientist Basic Cancer Research Training Program (UCLA Surgeon-Scientist BCRTP)$178,444
T32 · FY2025 · CA
Antibody-based therapeutic strategy for New World mammarenavirus hemorrhagic fever$753,610
R01 · FY2024 · AI · contact PI
Antibody-based therapeutic strategy for New World mammarenavirus hemorrhagic fever$767,610
R01 · FY2023 · AI · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$629,238
R01 · FY2020 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$621,421
R01 · FY2019 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$106,027
R01 · FY2019 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$860,660
R01 · FY2018 · CA · contact PI
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy$592,761
R01 · FY2018 · CA · contact PI
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy$554,058
R01 · FY2017 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$502,591
R01 · FY2017 · CA · contact PI
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy$556,615
R01 · FY2016 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$504,843
R01 · FY2016 · CA · contact PI
(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma$200,970
R21 · FY2016 · CA · contact PI
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL$196,920
R01 · FY2016 · CA · contact PI
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy$445,054
R01 · FY2015 · CA · contact PI
(PQC3) Immunological Basis of Health Disparities in Multiple Myeloma$167,475
R21 · FY2015 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$460,080
R01 · FY2014 · CA · contact PI
A Novel Anti-HER2/neu IgE for Breast Cancer Therapy$369,640
R01 · FY2014 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$148,320
R01 · FY2014 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$454,899
R01 · FY2013 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$140,921
R01 · FY2013 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$493,702
R01 · FY2012 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$503,602
R01 · FY2011 · CA · contact PI
Novel Nanopolymers to Inhibit Angiogenesis and Increase the Anti-tumor Immunity$543,040
R01 · FY2010 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$300,313
R01 · FY2009 · CA · contact PI
Development of an anti-PSA IgE to treat prostate cancer$158,851
R41 · FY2009 · CA
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$300,313
R01 · FY2008 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$86,240
R01 · FY2008 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$300,313
R01 · FY2007 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$84,011
R01 · FY2007 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$309,282
R01 · FY2006 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$54,333
R01 · FY2006 · CA · contact PI
Anti-TfR IgG3-Av: A New Drug Against Multiple Myeloma$252,423
R01 · FY2005 · CA
Universal Vectors for the Therapy of Cancer$147,865
K01 · FY2005 · CA
Universal Vectors for the Therapy of Cancer$145,130
K01 · FY2004 · CA
Universal Vectors for the Therapy of Cancer$115,477
K01 · FY2003 · CA
Universal Vectors for the Therapy of Cancer$112,900
K01 · FY2002 · CA
Universal Vectors for the Therapy of Cancer$110,398
K01 · FY2001 · CA